Related Experiment Video
Updated: Jun 19, 2026

07:36
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
5.4K
In response to: PSMA PET/CT cost-effectiveness analysis in the USA: a response to a published commentary
Adrien Holzgreve1, Wolfgang G Kunz2, Dirk Mehrens2
1Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistr, 15, 81377, Munich, Germany. Adrien.Holzgreve@med.lmu.de.
European Journal of Nuclear Medicine and Molecular Imaging
|August 18, 2023
Abstract
No abstract available in PubMed .
More Related Videos
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
455
07:45Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
Published on: October 25, 2024
415
Related Concept Videos
Positron Emission Tomography
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).